Pfizer Announces Approval of ELELYSO in Treatment of Type 1 Gaucher Disease - Pharmaceutical Technology

Latest Issue
PharmTech

Latest Issue
PharmTech Europe

Pfizer Announces Approval of ELELYSO in Treatment of Type 1 Gaucher Disease


Pfizer Inc. announced on Aug. 28 that FDA approved ELELYSO for injection in pediatric patients. ELELYSO is indicated for long-term enzyme replacement therapy (ERT) for adult and pediatric patients with a confirmed diagnosis of Type 1 Gaucher disease.

The safety and efficacy of ELELYSO in treating Type 1 Gaucher disease was assessed in two clinical trials consisting of pediatric patients. The first trial tested nine patients in a 12-month, multi-center, double-blind, randomized study in treatment-naïve patients aged 2-13 years. At the end of the 12-month study, therapeutic efficacy of ELELYSO was demonstrated, as measured by a decrease in spleen and liver volume and an increase in platelet count. The second trial consisted of five pediatric patients aged 6-16 years who were switched from imiglucerase to ELELYSO in a nine-month, multi-center, open-label, single-arm study in patients who had been receiving treatment with imiglucerase at dosages ranging from 9.5 units/kg to 60 units/kg every other week for a minimum of two years. ELELYSO was administered for nine months at the same dose as each patient’s previous imiglucerase dose, with relevant adjustments to maintain stability. Mean spleen and liver volume, platelet count, and hemoglobin value remained stable through nine months of ELELYSO treatment.

The recommended dosage of ELELSYO for treatment-naïve adult and pediatric patients four years of age and older is 60 units/kg of body weight administered every other week as a 60 to 120 minute intravenous infusion.

Source: Pfizer

ADVERTISEMENT

blog comments powered by Disqus
LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
|Monthly
| Weekly

Survey
What role should the US government play in the current Ebola outbreak?
Finance development of drugs to treat/prevent disease.
Oversee medical treatment of patients in the US.
Provide treatment for patients globally.
All of the above.
No government involvement in patient treatment or drug development.
Finance development of drugs to treat/prevent disease.
23%
Oversee medical treatment of patients in the US.
14%
Provide treatment for patients globally.
7%
All of the above.
47%
No government involvement in patient treatment or drug development.
9%
Jim Miller Outsourcing Outlook Jim MillerOutside Looking In
Cynthia Challener, PhD Ingredients Insider Cynthia ChallenerAdvances in Large-Scale Heterocyclic Synthesis
Jill Wechsler Regulatory Watch Jill Wechsler New Era for Generic Drugs
Sean Milmo European Regulatory WatchSean MilmoTackling Drug Shortages
New Congress to Tackle Health Reform, Biomedical Innovation, Tax Policy
Combination Products Challenge Biopharma Manufacturers
Seven Steps to Solving Tabletting and Tooling ProblemsStep 1: Clean
Legislators Urge Added Incentives for Ebola Drug Development
FDA Reorganization to Promote Drug Quality

Click here